SEC Tracker
Get the app

NextCure NXTC

NextCure Q3 FY23: net loss $14.3M; diluted EPS −$6.38

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers NextCure reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$14.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$6.38No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.5110-Q income statement, on EDGAR
  3. Cash and cash equivalents$19.5MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$12.8MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when NextCure files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Cellectar Biosciences CLRB public float $13M, Jun 30, 2025
  2. Synergy CHC SNYR public float $13M, Jun 30, 2025
  3. Cypherpunk Technologies CYPH public float $12M, Jun 30, 2025
  4. Earth Science Tech ETST public float $14M, Mar 31, 2026
  5. Cocrystal Pharma COCP public float $12M, Jun 30, 2025